Arun Sharma, PhD

Associate Professor, Department of Pharmacology
Penn State Cancer Institute
Cancer Institute, Next-Generation Therapies

2559 Citations
28 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

The major focus of Dr. Arun Sharma’s lab is the design and development of novel small drug-like molecules as potential cancer therapeutic and preventive agents, and testing them in various in vitro and in vivo cancer models.

This effort has resulted in the development of some potent anti-cancer agents and understanding of their efficacy, toxicity, pharmacokinetics, and mechanisms of action. The main strategies adapted for designing new agents include optimization of

naturally occurring agents;
existing drugs or agents that fail in clinical trials; and
lead compounds obtained from chemical library screening, to enhance potency, bioavailability and therapeutic/chemopreventive index.

An example of natural product optimization includes the development of ISC-4, an isosteric selenium analog of isothiocyanates that occur naturally in cruciferous vegetables. ISC-4 was shown to be a PI3K/Akt pathway inhibitor that effectively inhibited tumor growth in melanoma and colon cancer xenograft models, alone and in combination with standard of care. Further optimization of ISC-4 structure has now led to a dual Akt pathway/topoisomerase II inhibitor NISC-6 as a potential melanoma therapeutic.

Through extensive structure-activity studies based on Selenium-NSAID hybrid molecules, Dr. Sharma’s lab has recently discovered two potent small molecules: Se-Aspirin, published recently and already commercially available; and AS-10, a bis-aspirinyl-selenazolidine analog which has shown great potential as a cancer therapeutic, particularly for pancreatic cancer. p-XS-Asp, another Se-aspirin hybrid molecule developed recently, is orally bioavailable and effective in preventing against NNK induced lung tumorigenesis.

Apart from developing anti-cancer compounds, Dr. Sharma’s lab is also focusing on developing "smart antibiotics." The emphasis is on designing and synthesizing cationic bolaamphiphiles (CABs) as carrier compounds that can transport antisense oligonucleotide (ASO) into C. difficile to selectively target the genetic material in C. difficile.

Fingerprint Dive into the research topics where Arun Sharma is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

8 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

3 Finished
3 Active

A promising small molecule for pancreatic cancer therapy

Sharma, A.

National Institutes of Health

12/6/18 → 11/30/20

Project: Research project

In vivo agonist molecular probes for the dopamine D1 receptor

Mailman, R. & Sharma, A.

National Institutes of Health

2/15/18 → 1/31/21

Project: Research project

Cationic Bolaamphiphiles (CAB) and Phosphorothioate Gapmers as Antisense Therapy for C. difficile

Sharma, A. & Stewart, D.

National Institutes of Health

6/5/17 → 5/31/20

Project: Research project

A novel compound for colorectal cancer prevention

Sharma, A. & Sharma, A. K.

National Institutes of Health

7/11/14 → 3/31/17

Project: Research project

Development of a novel agent for lung cancer prevention

Sharma, A. & Sharma, A. K.

National Institutes of Health

7/9/12 → 6/30/14

Project: Research project